Video

Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

Author(s):

Hans Hammers, MD, PhD,Moshe Ornstein, MD

Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.

Related Videos
Tiago Biachi, MD, PhD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Alberto Montero, MD, MBA, CPHQ
Thomas Westbrook, MD, assistant professor, Rush University Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Chad Tang, MD
Martin H. Voss, MD
Martin H. Voss, MD
Alexandra Drakaki, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Related Content
David A. Braun, MD, PhD
November 9th 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

ESMO 2024
November 1st 2024

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

FDA
October 31st 2024

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC